Published Technical Disclosure Archive

Chimeric Stem Cell Tech: Multi-Industry Innovation

Publication ID: 24-11856927_0002_PTD
Published: October 26, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Chimeric Stem Cell Tech: Multi-Industry Innovation,” Published Technical Disclosure No. 24-11856927_0002_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856927_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent focused on treating inflammation in chimeric animals after birth. However, the chimeric technology has vast untapped potential. The present invention addresses the limitation of the original patent by exploring new industries and use cases, including agricultural livestock, crop yield improvement, skin condition treatment, personalized medicine, and tissue regeneration.

Novelty and Inventive Step

The novelty of the present invention lies in its expansion of chimeric technology into new fields, leveraging the core principles to address distinct challenges. The inventive step is the recognition of the broad applicability of chimeric technology and the development of specific solutions for various industries.

Alternative Embodiments and Variations

Alternative embodiments may include using different types of pluripotent cells, varying the administration methods of anti-inflammatory agents, or integrating chimeric technology with existing agricultural or medical practices. Variations may also involve adapting the technology for use in different species or developing new compositions for treating various diseases.

Potential Commercial Applications and Market

The present invention has significant commercial potential across multiple industries. In agriculture, the technology can improve crop yields and reduce livestock losses. In medicine, it can lead to breakthroughs in personalized treatment and tissue regeneration. The market for these applications is vast, with potential customers including agricultural companies, pharmaceutical firms, and medical research institutions.

CPC Classifications

SectionClassGroup
A A01 A01K67/0271
A A61 A61K31/573
A A61 A61P37/06
A A01 A01K2217/05
A A01 A01K2217/075
A A01 A01K2227/105
A A01 A01K2267/035
C C12 C12N15/09

Field of Art

Biotechnology and veterinary medicine, focusing on chimeric animal technologies, stem cell manipulation, and immunological interventions across species

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary science, molecular biology, or bioengineering, possessing expertise in pluripotent cell technologies, immunological modulation, and cross-species cellular engineering

Obviousness Rationale

A PHOSITA would recognize that the source patent's core principles of chimeric animal manipulation and inflammation control represent a foundational technology with broad applicability across multiple domains. The PTD's variations systematically extend these core principles by applying chimeric cell technologies to diverse fields like agriculture, personalized medicine, and tissue regeneration. Given the versatility of pluripotent cell technologies and the established methodologies for inflammation management, a skilled practitioner would find these extensions predictable and technically straightforward.

Obvious Combinations & Variations

Source Patent Element
Method of obtaining an adult chimeric animal with controlled immune response
PTD Variation
Agricultural livestock inflammation monitoring system using chimeric animal technologies
Obviousness Reasoning
Predictable extension of immune modulation techniques to agricultural contexts, representing a known approach to improving animal health management
Source Patent Element
Techniques for managing inflammation in chimeric animals post-birth
PTD Variation
Personalized medicine development using chimeric animal disease models
Obviousness Reasoning
Logical application of chimeric technology to create translational research platforms, utilizing established stem cell and immunological manipulation methods
Source Patent Element
Allogeneic and xenogeneic pluripotent cell transplantation methods
PTD Variation
Tissue regeneration approach introducing pluripotent cells into damaged tissue sites
Obviousness Reasoning
Well-known regenerative medicine technique leveraging established cellular engineering principles from the source patent
Source Patent Element
Anti-inflammatory agent administration in chimeric animals
PTD Variation
Composition for treating skin conditions using chimeric cell populations
Obviousness Reasoning
Straightforward adaptation of immunomodulatory techniques to dermatological applications, representing a predictable medical innovation
Source Patent Element
Generating chimeric organisms through pluripotent cell manipulation
PTD Variation
Chimeric plant generation for improved crop resistance
Obviousness Reasoning
Obvious technological transfer of cellular engineering principles from animal to plant biotechnology, representing a standard approach in cross-domain innovation
35 U.S.C. § 103 Summary: Based on US Patent 11856927's comprehensive disclosure of chimeric animal technologies and inflammation management, the present publication demonstrates that the claimed variations represent obvious extensions of known scientific principles. A person having ordinary skill in the art would readily recognize the systematic application of pluripotent cell manipulation techniques across diverse technological domains as a predictable innovation, thus rendering subsequent patent claims obvious and non-patentable.

Original Patent Information

Patent NumberUS 11,856,927
TitleFinding and treatment of inflammation after birth in chimeric animal
Assignee(s)The University of Tokyo